https://scholars.lib.ntu.edu.tw/handle/123456789/597544
標題: | Primary cardiac sarcomas: A multi-national retrospective review | 作者: | WEI-WU CHEN Loong H.H. Srikanthan A. Zer A. Barua R. Butany J. Cusimano R.J. Liang Y.-C. Chang C.-H. Iakobishvili Z. Razak A.R.A. Lewin J. |
關鍵字: | primary cardiac sarcoma; radiotherapy; sarcoma chemotherapy; surgery | 公開日期: | 2019 | 出版社: | Blackwell Publishing Ltd | 卷: | 8 | 期: | 1 | 起(迄)頁: | 104-110 | 來源出版物: | Cancer Medicine | 摘要: | Background: Primary cardiac sarcoma (PCS) is a rare but often fatal disease. The current study aimed to analyze the impact of baseline demographics, local and systemic therapies in a contemporary cohort. Methods: Clinical records of PCS across six institutions in three continents were reviewed. Kaplan-Meier method was used to estimate survival. Cox proportional hazard model was used to determine variables impacting progression-free survival (PFS) or overall survival (OS). Results: Sixty-one patients with PCS (1996-2016) were identified. The median age at diagnosis was 46 (range 18-79); 36% (n?=?22) presented with metastatic disease. The most common histology was angiosarcoma (n?=?24, 39%). A total of 46 patients received surgery (75%) but only 5 (8%) patients achieved R0 resection. Multi-modality treatment to the primary tumor was given to 28 patients (46%; localized disease 23/39 (59%); metastatic disease 5/22 (23%)). The median OS for the entire cohort was 17.5?months (95% CI 9.5-20.6), with seven (11%) patients surviving longer than 36?months. On multi-variate analysis, age <65 (P?=?0.01) was the only significant favorable prognostic factor. For first-line palliative chemotherapy, the median PFS was 4.4?months (95% CI 2.9-7.7?months). The best response for first-line chemotherapy was 32% (CR?=?1, PR?=?9). No significant improvement in OS was identified in patients presenting throughout the 20-year period of this review. Conclusion: Younger age at diagnosis was associated with improved outcome although the prognosis of PCS remains poor. Given the lack of improvement in survival, further dedicated research is required. ? 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060546100&doi=10.1002%2fcam4.1897&partnerID=40&md5=02a93a82949a60a3cd822eef7e95c905 https://scholars.lib.ntu.edu.tw/handle/123456789/597544 |
ISSN: | 2045-7634 | DOI: | 10.1002/cam4.1897 | SDG/關鍵字: | adult; age; aged; angiosarcoma; Article; cancer chemotherapy; cancer prognosis; cardiovascular system cancer; clinical feature; female; histology; human; major clinical study; male; overall survival; palliative therapy; primary cardiac sarcoma; primary tumor; priority journal; progression free survival; retrospective study; survival rate; trend study; tumor localization; tumor volume; adolescent; heart tumor; middle aged; pathology; sarcoma; survival analysis; treatment outcome; young adult; Adolescent; Adult; Aged; Female; Heart Neoplasms; Humans; Male; Middle Aged; Retrospective Studies; Sarcoma; Survival Analysis; Treatment Outcome; Tumor Burden; Young Adult |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。